An academic spin-off biotech with only a handful of people on board was preparing for their new biological entity for clinical development. For the drug product itself, they needed to

Speaker: Ion Tcacencu –  is an ATMP expert with over 17 years of experience as scientist within regenerative medicine and immunology, being responsible for projects developing new ATMPs. Ready to explore the cutting-edge

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge

Dr. Andrew Catchpole, Chief Scientific Officer discusses hVIVO’s bespoke human challenge model development services focusing on our most recent Flu B model. He highlights the various stages of this contract

Pharmaceutical services firm hVivo, formerly Open Orphan, saw revenues jump by 52pc in the first half of the year. The Dublin-listed pharmaceutical services company founded by businessman Cathal Friel, has

Hvivo, the Dublin-listed pharmaceutical services company founded by businessman Cathal Friel, has said it expects to deliver double-digit topline growth for the first six months of the year, as well

Clinical trial firm hVIVO has signed a £13.1 million (€15.2m) contract with a ‘top five global pharmaceutical client’ to produce a human trial challenge for a new influenza B vaccine. The trial

Stock market listed pharmaceutical services firm hVIVO has signed a £13.1m (€15.2m) contract with a large global pharmaceutical company to develop an influenza B virus challenge model. Irish founded hVIVO,

Hvivo, the pharmaceutical services company formerly known as Open Orphan, has reported a jump in trading revenues in the first half of the year compared with the same period last